Arsenic trioxide - An old drug rediscovered.
Over the last 17 years, clinical trials conducted worldwide have demonstrated the efficacy of arsenic trioxide (As(2)O(3)) in the treatment of relapsed acute promyelocytic leukemia (APL). Currently, the role of As(2)O(3) in front-line therapy is under investigation. Recent trials in the US have demonstrated that the addition of As(2)O(3) to standard treatment regimens improves survival outcomes in patients with APL and may allow a reduction in cytotoxic chemotherapy exposure. As(2)O(3) has also shown efficacy in other malignancies, particularly multiple myeloma and myelodysplastic syndromes. Therapeutic doses of As(2)O(3) are well tolerated, with no evidence of long-term toxicity. Adverse events include APL differentiation syndrome, electrocardiographic abnormalities, and mild elevations in liver enzymes. This review highlights trials investigating the role of As(2)O(3) in induction and consolidation for newly diagnosed APL, as well as its role in other hematologic malignancies. The chemistry, mechanisms of action, and clinical side effects of As(2)O(3) are also discussed.
Emadi
Ashkan
A
Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231-1000, United States. aemadi1@jhmi.edu
Gore
Steven D
SD
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy*; D010087:Oxides / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D001152:Arsenicals; D010087:Oxides; D000077237:Arsenic Trioxide
Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5328-35
15044693
Leuk Res. 2004 Aug;28(8):791-803
15203277
J Clin Oncol. 2001 Sep 15;19(18):3852-60
11559723
Leukemia. 2002 Sep;16(9):1888
12200720
Annu Rev Pharmacol Toxicol. 1997;37:397-419
9131259
Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3342-7
19225113
J Biol Chem. 1992 Jun 5;267(16):11366-73
1597467
Zhonghua Wai Ke Za Zhi. 2006 Jun 15;44(12):805-8
16889724
Clin Cancer Res. 2007 Mar 15;13(6):1762-8
17363530
Blood. 1997 May 1;89(9):3487-8
9129058
Science. 1997 Feb 21;275(5303):1132-6
9027315
Leukemia. 2004 Sep;18(9):1518-21
15269785
Cancer Res. 2003 Apr 15;63(8):1853-9
12702573
Blood. 2009 Jun 25;113(26):6528-32
19411628
J Biol Chem. 1999 Jun 18;274(25):17941-5
10364241
N Engl J Med. 1998 Nov 5;339(19):1341-8
9801394
Br J Haematol. 1997 Dec;99(3):625-31
9401076
Cancer Res. 1999 Mar 1;59(5):1041-8
10070961
J Clin Oncol. 2006 Jun 1;24(16):2456-64
16651647
Br J Haematol. 2006 Oct;135(2):174-83
17010047
Leuk Lymphoma. 2004 Dec;45(12):2387-401
15621751
Hematol J. 2004;5(2):130-4
15048063
Cell. 1994 Jan 28;76(2):333-43
8293467
Clin Cancer Res. 2002 Dec;8(12):3658-68
12473574
Blood. 1999 Jan 1;93(1):268-77
9864170
Blood. 1997 May 1;89(9):3354-60
9129042
J Clin Oncol. 2006 Dec 20;24(36):5703-10
17116939
Haematologica. 2006 Dec;91(12):1722-3
17145617
Br J Haematol. 2002 Mar;116(3):555-63
11849211
Blood. 2005 May 15;105(10):4004-12
15677571
J Clin Oncol. 2006 Jun 1;24(16):2465-71
16651646
J Biol Chem. 2000 Nov 17;275(46):36062-6
10967126
Leuk Res. 2007 Nov;31(11):1585-7
17416415
Blood. 2004 Feb 15;103(4):1237-43
14576047
Biol Pharm Bull. 2006 May;29(5):1022-7
16651738
Oncologist. 2001;6 Suppl 2:3-10
11331434
Haematologica. 2006 Aug;91(8):1105-8
16870552
Biol Blood Marrow Transplant. 2008 Dec;14(12):1401-7
19041063
Leukemia. 2003 Aug;17(8):1499-507
12886236
J Clin Oncol. 2010 Feb 20;28(6):1047-53
20085935
Hematol Oncol. 2009 Mar;27(1):11-6
18668698
Nature. 2000 Oct 12;407(6805):770-6
11048727
Int J Biochem Cell Biol. 2008;40(5):1016-29
18160327
J Biol Chem. 1999 Apr 23;274(17):11549-56
10206961
Leukemia. 2002 Sep;16(9):1835-7
12200700
Biochem Pharmacol. 1998 Jun 1;55(11):1747-58
9714292
Leukemia. 1998 Sep;12(9):1383-91
9737686
Biochem Biophys Res Commun. 2001 Aug 31;286(4):726-34
11520058
Blood. 2007 Jul 1;110(1):59-66
17374742
Med Oncol. 2006;23(2):263-72
16720927
Blood. 2008 Mar 1;111(5):2505-15
18299451
J Natl Cancer Inst. 1999 May 5;91(9):772-8
10328107
Nat Genet. 1998 Nov;20(3):266-72
9806545
Chem Res Toxicol. 2004 Jan;17(1):95-103
14727923
Cancer Lett. 2008 Jul 18;266(1):53-9
18362051
Cancer. 2005 Oct 15;104(8):1687-92
16130126
Haematologica. 2007 May;92(5):719-20
17488707
Yao Xue Xue Bao. 2008 Jan;43(1):35-43
18357729
Blood. 2009 Feb 26;113(9):1875-91
18812465
Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4578-83
15070760
Invest New Drugs. 2002 Aug;20(3):327-30
12201495
Blood. 2001 Aug 1;98(3):805-13
11468182
Am J Med Sci. 1988 Aug;296(2):85-6
2456695
Cancer Res. 2002 Jul 15;62(14):3893-903
12124315
Cancer Res. 2003 May 1;63(9):2103-8
12727826
Blood. 2006 Apr 1;107(7):2627-32
16352810
Br J Haematol. 2004 May;125(4):470-6
15142117
Inorg Chem. 2005 Apr 18;44(8):2964-72
15819584
Cancer Res. 2000 Jun 1;60(11):3065-71
10850458
Blood. 1997 May 1;89(9):3345-53
9129041
Cancer Chemother Pharmacol. 2007 Mar;59(4):485-93
16937107
Invest New Drugs. 2007 Feb;25(1):77-84
16937079
J Clin Oncol. 2009 Feb 1;27(4):504-10
19075265
Exp Cell Res. 1999 Jun 15;249(2):413-21
10366441
Cancer. 2008 Mar 1;112(5):1131-8
18286511
Leukemia. 2005 Jan;19(1):154-6
15496977
Cancer. 2008 Nov 1;113(9):2504-11
18825661
Leuk Res. 2008 Feb;32(2):251-4
17920679
Blood. 1996 Aug 1;88(3):1052-61
8704214